Abstract 465P
Background
This study evaluated the quality of oncological care of people with mental illness at an outer metropolitan centre.
Methods
A retrospective review of multidisciplinary team meetings (MDTs) was conducted and those with comorbid mental illness (“cases”) were identified. Demographic, psychiatric and oncological data were collected. Mental illness was stratified to 3 categories – Cat 1: mild affective disorders (uncomplicated depression/anxiety); Cat 2: complicated affective disorders (e.g. depression/anxiety with prior suicide attempt, hospitalisation and/or case management, substance use disorder and post-traumatic stress disorder); and Cat 3: severe mental illness (SMI) (e.g. bipolar affective disorder and schizophrenia). Patients without mental illness (“controls”) were randomly selected from the same tumour stream MDTs. Comparison between cases and controls was performed using Fisher’s exact test.
Results
Between 2021-2022, 853 patients were discussed at MDTs. 170 (20%) cases were identified, of whom 57%, 29% and 14% were in Cat 1, 2 and 3 respectively. Corresponding 170 controls were selected at random. Median age for cases was 65 vs. 71 for controls, p=0.03. No differences in sex and ethnicity were found. Cat 3 cases had the highest proportion receiving government financial aid (87%) vs. controls (57%) (Cat 1: 68%, Cat 2: 78%) p=0.001. Cat 3 cases also had the highest rates of ≥3 non-attendances to appointments (22%) vs. controls (7%) (Cat 1: 12%, Cat 2: 18%) p=0.006. Cases were found to have higher rates of metastatic disease at presentation (26% vs. 15% for controls, p=0.01). For patients offered active palliative treatment (n=80), cases had reduced adherence to the recommended treatment plan (70% vs. 91% for controls, p=0.03). Of those offered curative treatment (n=237), Cat 3 cases had the highest rates of cancer recurrence (33%) vs. controls (9%) (Cat 1: 12%, Cat 2: 18%) p=0.03.
Conclusions
Mental illness was associated with poorer cancer outcomes with increasing severity associated with even poorer outcomes, potentially reflecting higher rates of treatment non-adherence. This institutional study suggests that people with SMI have increased needs in navigating cancer care and highlights a need to examine this on a larger scale.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Z.W. Wong: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Other, Travel grant: Pfizer. Y. Antill: Financial Interests, Personal, Invited Speaker: GSK, MSD, AstraZeneca, Lilly, Eisai; Financial Interests, Institutional, Research Funding: AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: GSK, MSD, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract